CA2718639C - Systeme de delivrance de methylphenidate a liberation etendue - Google Patents

Systeme de delivrance de methylphenidate a liberation etendue Download PDF

Info

Publication number
CA2718639C
CA2718639C CA2718639A CA2718639A CA2718639C CA 2718639 C CA2718639 C CA 2718639C CA 2718639 A CA2718639 A CA 2718639A CA 2718639 A CA2718639 A CA 2718639A CA 2718639 C CA2718639 C CA 2718639C
Authority
CA
Canada
Prior art keywords
delivery system
drug delivery
controlled release
therapeutic drug
hpmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2718639A
Other languages
English (en)
Other versions
CA2718639A1 (fr
Inventor
Vinayak Pathak
Naresh Talwar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FINCHLEY RESEARCH & DEVELOPMENT INC.
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Priority to CA2718639A priority Critical patent/CA2718639C/fr
Publication of CA2718639A1 publication Critical patent/CA2718639A1/fr
Application granted granted Critical
Publication of CA2718639C publication Critical patent/CA2718639C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un système dadministration de médicament thérapeutique à libération prolongée comprenant: une composition de matrice de noyau renfermant un principe actif tel qu'un stimulant du SNC (p.ex. du méthylphénidate) et un agent régulant la libération (HPMC -K4M, HPMC-K IOOM CR ou HPMC-K 15 M CR); ainsi qu'une composition d'enrobage à libération contrôlée recouvrant la matrice de noyau faite de polymères à libération contrôlée tels que l'Eudragit RL 3OD. Ledit système s'administre une ou deux fois par jour. L'invention porte également sur le procédé de fabrication de ce système dadministration de médicament thérapeutique à libération prolongée.
CA2718639A 2008-03-27 2009-03-26 Systeme de delivrance de methylphenidate a liberation etendue Active CA2718639C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2718639A CA2718639C (fr) 2008-03-27 2009-03-26 Systeme de delivrance de methylphenidate a liberation etendue

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,627,198 2008-03-27
CA002627198A CA2627198A1 (fr) 2008-03-27 2008-03-27 Systeme d'administration de drogue therapeutique a liberation prolongee de methylphenidate
PCT/CA2009/000369 WO2009117819A1 (fr) 2008-03-27 2009-03-26 Système de délivrance de méthylphénidate à libération étendue
CA2718639A CA2718639C (fr) 2008-03-27 2009-03-26 Systeme de delivrance de methylphenidate a liberation etendue

Publications (2)

Publication Number Publication Date
CA2718639A1 CA2718639A1 (fr) 2009-10-01
CA2718639C true CA2718639C (fr) 2018-05-01

Family

ID=41112885

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002627198A Abandoned CA2627198A1 (fr) 2008-03-27 2008-03-27 Systeme d'administration de drogue therapeutique a liberation prolongee de methylphenidate
CA2718639A Active CA2718639C (fr) 2008-03-27 2009-03-26 Systeme de delivrance de methylphenidate a liberation etendue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002627198A Abandoned CA2627198A1 (fr) 2008-03-27 2008-03-27 Systeme d'administration de drogue therapeutique a liberation prolongee de methylphenidate

Country Status (2)

Country Link
CA (2) CA2627198A1 (fr)
WO (1) WO2009117819A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
DK2688557T3 (da) 2011-03-23 2017-11-27 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
ID29852A (id) * 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
EP1474123A1 (fr) * 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Formulation pharmaceutique a liberation controlee contenant de la venlafaxine
CN1985810A (zh) * 2006-07-28 2007-06-27 中国人民解放军第二军医大学 盐酸哌甲酯缓控释胶囊及其制备方法

Also Published As

Publication number Publication date
WO2009117819A1 (fr) 2009-10-01
CA2627198A1 (fr) 2009-09-27
CA2718639A1 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
CA2718639C (fr) Systeme de delivrance de methylphenidate a liberation etendue
US6217904B1 (en) Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second CNS stimulant
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
US9717701B2 (en) Compositions for overcoming resistance to tramadol
TWI590835B (zh) 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物
US20110123575A1 (en) Modified release niacin formulations
WO2011020032A2 (fr) Forme pharmaceutique
WO2007070840A2 (fr) Formulations pharmaceutiques d'escitalopram modifiees et a liberation pulsatile
US20130251793A1 (en) Pharmaceutical composition comprising phentermine and topiramate
EP3638211B1 (fr) Compositions pharmaceutiques à libération prolongée retardée
KR20160127405A (ko) 리바스티그민 함유 서방출 의약조성물
EP2536688A1 (fr) Formes posologiques stables de levomilnacipran
JP2024524757A (ja) 多粒子医薬組成物
AU2021201351B1 (en) Dosage form providing prolonged release of a salt of Tapentadol with L-(+)-tartaric acid
SG187172A1 (en) Controlled release dosage form comprising quetiapine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140121